ProQR Therapeutics (PRQR) Registration Filing summary

Company overview and business model

• Focuses on RNA editing therapeutics using proprietary Axiomer platform to address diseases with high unmet medical need, especially in liver and CNS disorders.

• Pipeline includes lead program AX-0810 for cholestatic diseases, AX-2402 for Rett Syndrome, AX-1412 for cardiovascular diseases, and AX-2911 for metabolic dysfunction-associated steatohepatitis.

• Engaged in strategic collaborations, notably with Eli Lilly, to expand the application of its RNA editing technology.

• Maintains a robust intellectual property estate in the ADAR RNA editing space and seeks further partnerships to advance its platform.

Financial performance and metrics

• As of December 31, 2024, cash and cash equivalents totaled €149.4 million, with total debt of €17.2 million and equity of €88.6 million.

• Raised €518.0 million in gross proceeds from public offerings and private placements to date.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by the selling shareholder; proceeds go to the selling shareholder.

• Agreed to pay certain registration expenses, excluding commissions or discounts attributable to the sale.